EP3297702A4 - Méthodes et compositions permettant de traiter des troubles associés au vieillissement - Google Patents

Méthodes et compositions permettant de traiter des troubles associés au vieillissement Download PDF

Info

Publication number: EP3297702A4
Authority: EP; European Patent Office
Prior art keywords: aging; compositions; methods; conditions associated; treating conditions
Prior art date: 2015-05-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP16797159.7A

Other languages

German (de)

English (en)

Other versions

EP3297702A2 (fr

Inventor

Anton Wyss-Coray

Saul A. VILLEDA

Karoly Nikolich

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Us Government Represented By Department Of V

University of California San Diego UCSD

Leland Stanford Junior University

Alkahest Inc

Original Assignee

University of California

US Department of Veterans Affairs

University of California Berkeley

University of California San Diego UCSD

Leland Stanford Junior University

Alkahest Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-18

Filing date

2016-05-17

Publication date

2019-01-16

2016-05-17 Application filed by University of California, US Department of Veterans Affairs, University of California Berkeley, University of California San Diego UCSD, Leland Stanford Junior University, Alkahest Inc filed Critical University of California

2016-05-17 Priority to EP21162695.7A priority Critical patent/EP3892315A1/fr

2018-03-28 Publication of EP3297702A2 publication Critical patent/EP3297702A2/fr

2019-01-16 Publication of EP3297702A4 publication Critical patent/EP3297702A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/07—Proteins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Psychiatry (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Mycology (AREA)

EP16797159.7A 2015-05-18 2016-05-17 Méthodes et compositions permettant de traiter des troubles associés au vieillissement Withdrawn EP3297702A4 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP21162695.7A EP3892315A1 (fr)	2015-05-18	2016-05-17	Méthodes et compositions permettant de traiter des troubles associés au vieillissement

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562163222P	2015-05-18	2015-05-18
PCT/US2016/032907 WO2016187217A2 (fr)	2015-05-18	2016-05-17	Méthodes et compositions permettant de traiter des troubles associés au vieillissement

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP21162695.7A Division EP3892315A1 (fr)	2015-05-18	2016-05-17	Méthodes et compositions permettant de traiter des troubles associés au vieillissement

Publications (2)

Publication Number	Publication Date
EP3297702A2 EP3297702A2 (fr)	2018-03-28
EP3297702A4 true EP3297702A4 (fr)	2019-01-16

Family

ID=57320543

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP16797159.7A Withdrawn EP3297702A4 (fr)	2015-05-18	2016-05-17	Méthodes et compositions permettant de traiter des troubles associés au vieillissement
EP21162695.7A Withdrawn EP3892315A1 (fr)	2015-05-18	2016-05-17	Méthodes et compositions permettant de traiter des troubles associés au vieillissement

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP21162695.7A Withdrawn EP3892315A1 (fr)	2015-05-18	2016-05-17	Méthodes et compositions permettant de traiter des troubles associés au vieillissement

Country Status (11)

Country	Link
EP (2)	EP3297702A4 (fr)
JP (2)	JP7134089B2 (fr)
KR (1)	KR20180030965A (fr)
CN (2)	CN116687969A (fr)
AU (4)	AU2016265948B2 (fr)
CA (1)	CA2984645C (fr)
EA (2)	EA202091057A3 (fr)
HK (1)	HK1248153A1 (fr)
IL (1)	IL255319B2 (fr)
NZ (1)	NZ738184A (fr)
WO (1)	WO2016187217A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10626399B2 (en)	2010-01-28	2020-04-21	The Board Of Trustees Of The Leland Stanford Junior University	Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US20160208011A1 (en)	2010-01-28	2016-07-21	The Board Of Trustees Of The Leland Stanford Junior University	Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en)	2010-01-28	2019-11-26	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for treating aging-associated impairments
US9161968B2 (en)	2011-04-08	2015-10-20	The Board Of Trustees Of The Leland Stanford Junior University	Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
NZ720949A (en)	2013-12-09	2019-03-29	Univ Leland Stanford Junior	Methods and compositions for treating aging-associated conditions
US10905779B2 (en)	2013-12-09	2021-02-02	The Board Of Trustees Of The Leland Stanford Junior University	Methods for screening human blood products comprising plasma using immunocompromised rodent models
SI3307296T1 (sl)	2015-06-15	2022-04-29	The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel	TIMP2 za uporabo pri zdravljenju s starostjo povezanih stanj
JP6837486B2 (ja) *	2015-12-15	2021-03-03	ザボードオブトラスティーズオブザリーランドスタンフォードジュニアユニバーシティＴｈｅＢｏａｒｄｏｆＴｒｕｓｔｅｅｓｏｆｔｈｅＬｅｌａｎｄＳｔａｎｆｏｒｄＪｕｎｉｏｒＵｎｉｖｅｒｓｉｔｙ	加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法
ES2900302T3 (es)	2016-04-28	2022-03-16	Alkahest Inc	Fracciones de plasma como terapia para el crecimiento y la progresión del tumor
EA039316B1 (ru)	2016-10-24	2022-01-12	Алкахест, Инк.	Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
US11040068B2 (en)	2017-04-26	2021-06-22	Alkahest, Inc.	Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
DK3615057T3 (da)	2017-04-26	2024-01-02	Alkahest Inc	Doseringsskema til behandling af kognitive svækkelser med blodplasmaprodukter
IL282227B2 (en)	2018-10-26	2024-08-01	Alkahest Inc	Use of plasma and plasma fractions to improve pain, wound healing and recovery after surgery
CN113081079B (zh) *	2021-03-30	2022-04-22	中国科学院生态环境研究中心	血桥限位器

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020143283A1 (en) *	1997-07-30	2002-10-03	Andrew Braverman	Material for removing beta-2 microglobulin from blood
WO2011094535A2 (fr) *	2010-01-28	2011-08-04	The Board Of Trustees Of The Leland Stanford Junior University	Biomarqueurs du vieillissement pour le détection et le traitement de troubles

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0236509B1 (fr)	1985-09-19	1993-02-10	Toray Industries, Inc.	Colonne d'extraction de b2 microglobuline
DE3887114D1 (de)	1987-12-11	1994-02-24	Akzo Nv	Biocompatible Dialysemembran aus Cellulose mit erhöhter Beta-2-Microglobulinadsorption.
FR2646607B1 (fr)	1989-05-03	1991-08-30	Inst Nat Sante Rech Med	Anticorps monoclonaux anti-b2 microglobuline
US5614396A (en)	1990-06-14	1997-03-25	Baylor College Of Medicine	Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
AU664976B2 (en)	1990-08-29	1995-12-14	Gene Pharming Europe Bv	Homologous recombination in mammalian cells
FR2685346B1 (fr)	1991-12-18	1994-02-11	Cis Bio International	Procede de preparation d'arn double-brin, et ses applications.
US5240614A (en)	1992-01-10	1993-08-31	Baxter International Inc.	Process for removing unwanted materials from fluids and for producing biological products
AU7623194A (en)	1993-09-03	1995-03-22	Vpi Holdings Ltd.	Oligonucleotides with rna cleavage activity
CA2183992A1 (fr)	1994-02-23	1995-08-31	Dan T. Stinchcomb	Procede et reactif inhibiteur de l'expression de genes concernant une affection
FR2722411B1 (fr)	1994-07-18	1996-10-04	Union Pharma Scient Appl	Immunonanoparticules revetues d'anticorps monoclonaux anti-beta2 microglobuline et leur utilisation pour la prophylaxie et/ou le traitement de pathologies dues a une infection par le virus hiv
US5780296A (en)	1995-01-17	1998-07-14	Thomas Jefferson University	Compositions and methods to promote homologous recombination in eukaryotic cells and organisms
AU705616B2 (en)	1995-04-21	1999-05-27	Cell Genesys, Inc.	Generation of large genomic DNA deletions
US5776744A (en)	1995-06-07	1998-07-07	Yale University	Methods and compositions for effecting homologous recombination
US5925544A (en)	1996-11-18	1999-07-20	Novo Nordisk A/S	Method of homologous recombination followed by in vivo selection of DNA amplification
US5830698A (en)	1997-03-14	1998-11-03	Idec Pharmaceuticals Corporation	Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US5948653A (en)	1997-03-21	1999-09-07	Pati; Sushma	Sequence alterations using homologous recombination
US5904663A (en)	1997-07-30	1999-05-18	Braverman; Andrew	Method of removing beta-2 microglobulin from blood
US20020159995A1 (en)	1997-07-30	2002-10-31	Renal Tech International	Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing
AUPR748501A0 (en)	2001-09-04	2001-09-27	Life Therapeutics Limited	Renal dialysis
US7066900B2 (en)	1998-12-23	2006-06-27	Life Therapeutics	Removal of metabolic components from blood
AUPP790898A0 (en)	1998-12-23	1999-01-28	Life Therapeutics Limited	Renal dialysis
CA2358949A1 (fr)	1999-01-22	2000-07-27	Robert M. Strom	Resine de divinylbenzene a surface modifiee pourvue d'un revetement hemocompatible
JP2003526367A (ja)	2000-03-16	2003-09-09	ジェネティカインコーポレイテッド	Ｒｎａ干渉の方法とｒｎａ干渉組成物
US7553484B2 (en)	2001-06-05	2009-06-30	The Regents Of The University Of California	Modulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) molecule
CA2936534C (fr)	2001-07-23	2021-01-26	The Board Of Trustees Of Leland Stanford Junior University	Methodes et compositions pour l'inhibition induite par l'arni de l'expression genetique chez des mammiferes
US20030180811A1 (en)	2002-03-11	2003-09-25	Montero-Julian Felix A.	Immunoassays for beta2-microglobulin
US7341721B2 (en)	2002-04-12	2008-03-11	The Board Of Trustees Of The University Of Arkansas	β2-microglobulin (β2m) and anti-β2m binding agents as anti-cancer therapeutics
US7037276B2 (en)	2002-07-02	2006-05-02	Precision Medical Devices, Inc.	Biopsy device
US20040127445A1 (en)	2002-08-28	2004-07-01	Chondrogene Limited	Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
WO2004048583A2 (fr)	2002-11-22	2004-06-10	Institut Clayton De La Recherche	Compositions et systemes destines a la regulation genique
GB0307206D0 (en)	2003-03-28	2003-04-30	Axordia Ltd	Hyperproliferation
WO2006130949A1 (fr)	2005-06-08	2006-12-14	Replicor Inc.	Molecules contre des maladies liees a l'amyloide et leur utilisation
US8211310B2 (en)	2006-11-20	2012-07-03	Cytosorbents, Inc.	Size-selective polymer system
ES2394841T5 (es) *	2007-12-06	2021-10-29	Asahi Kasei Medical Co Ltd	Membrana de fibras huecas porosa para el tratamiento de la sangre
CN102223896A (zh)	2008-08-07	2011-10-19	西塞医疗中心	抗-β-2-微球蛋白试剂及其用途
CA2739076A1 (fr)	2008-10-02	2010-04-08	Celtaxsys, Inc.	Methodes de modulation de la chimiotaxie negative de cellules immunitaires
US8754034B2 (en)	2009-02-06	2014-06-17	The Regents Of The University Of California	Structure-based design of peptide inhibitors of amyloid fibrillation
US20130331327A1 (en)	2012-06-08	2013-12-12	Vittorio Bellotti	Variant Beta2-microglobulin, characterization of the same and applications thereof
EP2781523A1 (fr)	2013-03-18	2014-09-24	Miltenyi Biotec GmbH	Analogues oligonucléotides lipophiles
JP6364488B2 (ja) *	2013-11-26	2018-07-25	ユニバーシティーオブノーステキサスヘルスサイエンスセンターアットフォートワースＵｎｉｖｅｒｓｉｔｙＯｆＮｏｒｔｈＴｅｘａｓＨｅａｌｔｈＳｃｉｅｎｃｅＣｅｎｔｅｒＡｔＦｏｒｔＷｏｒｔｈ	認知欠損を治療するための個別化医療的手法

2016
- 2016-05-17 AU AU2016265948A patent/AU2016265948B2/en not_active Ceased
- 2016-05-17 JP JP2018512817A patent/JP7134089B2/ja active Active
- 2016-05-17 CA CA2984645A patent/CA2984645C/fr active Active
- 2016-05-17 WO PCT/US2016/032907 patent/WO2016187217A2/fr not_active Ceased
- 2016-05-17 EA EA202091057A patent/EA202091057A3/ru unknown
- 2016-05-17 KR KR1020177035957A patent/KR20180030965A/ko not_active Ceased
- 2016-05-17 EP EP16797159.7A patent/EP3297702A4/fr not_active Withdrawn
- 2016-05-17 EP EP21162695.7A patent/EP3892315A1/fr not_active Withdrawn
- 2016-05-17 HK HK18107779.2A patent/HK1248153A1/zh unknown
- 2016-05-17 CN CN202310374205.5A patent/CN116687969A/zh active Pending
- 2016-05-17 CN CN201680028881.5A patent/CN107921188A/zh active Pending
- 2016-05-17 EA EA201792437A patent/EA035799B1/ru unknown
- 2016-05-17 NZ NZ73818416A patent/NZ738184A/en not_active IP Right Cessation
2017
- 2017-10-30 IL IL255319A patent/IL255319B2/en unknown
2019
- 2019-02-26 AU AU2019201337A patent/AU2019201337B9/en not_active Ceased
2020
- 2020-07-28 AU AU2020210181A patent/AU2020210181B2/en not_active Ceased
2021
- 2021-01-29 JP JP2021013639A patent/JP7323561B2/ja active Active
2022
- 2022-08-25 AU AU2022221494A patent/AU2022221494A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020143283A1 (en) *	1997-07-30	2002-10-03	Andrew Braverman	Material for removing beta-2 microglobulin from blood
WO2011094535A2 (fr) *	2010-01-28	2011-08-04	The Board Of Trustees Of The Leland Stanford Junior University	Biomarqueurs du vieillissement pour le détection et le traitement de troubles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A NIEZGODA ET AL: "The effect of cladribine treatment on beta-2 microglobin in the cerebrospinal fluid and serum of patients with multiple sclerosis", NEUROL NEUROCHIR POL. 2000 MAR-APR;34(2, 1 March 2000 (2000-03-01), pages 281 - 287, XP055531915, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/10962721> [retrieved on 20181210] *
S. GIORGETTI ET AL: "2-Microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity", NEPHROLOGY DIALYSIS TRANSPLANTATION., vol. 24, no. 4, 1 January 2009 (2009-01-01), GB, pages 1176 - 1181, XP055532705, ISSN: 0931-0509, DOI: 10.1093/ndt/gfn623 *

Also Published As

Publication number	Publication date
HK1248153A1 (zh)	2018-10-12
EP3892315A1 (fr)	2021-10-13
JP2021073264A (ja)	2021-05-13
AU2019201337A1 (en)	2019-03-21
JP2018518530A (ja)	2018-07-12
CA2984645C (fr)	2023-01-10
IL255319A0 (en)	2017-12-31
WO2016187217A2 (fr)	2016-11-24
WO2016187217A3 (fr)	2017-01-05
CN116687969A (zh)	2023-09-05
CA2984645A1 (fr)	2016-11-24
AU2016265948A1 (en)	2018-01-04
EA202091057A2 (ru)	2020-12-30
AU2020210181A1 (en)	2020-08-13
AU2016265948B2 (en)	2018-12-06
JP7134089B2 (ja)	2022-09-09
EA035799B1 (ru)	2020-08-12
KR20180030965A (ko)	2018-03-27
IL255319B (en)	2022-11-01
JP7323561B2 (ja)	2023-08-08
EP3297702A2 (fr)	2018-03-28
AU2019201337B9 (en)	2020-05-21
NZ738184A (en)	2019-09-27
IL255319B2 (en)	2023-03-01
AU2020210181B2 (en)	2022-05-26
AU2022221494A1 (en)	2022-09-29
AU2019201337B2 (en)	2020-05-14
EA201792437A1 (ru)	2018-04-30
EA202091057A3 (ru)	2021-03-31
CN107921188A (zh)	2018-04-17

Publication	Publication Date	Title
EP3297702A4 (fr)	2019-01-16	Méthodes et compositions permettant de traiter des troubles associés au vieillissement
EP3307296A4 (fr)	2019-01-16	Procédés et compositions pour traiter des états associés au vieillissement
EP3471745A4 (fr)	2020-01-22	Procédés et compositions pour réduire le stress oxydatif
EP3328377A4 (fr)	2019-03-13	Compositions et méthodes pour thérapies immuno-oncologiques
IL257252A (en)	2018-03-29	Methods of treating fgf21-associated disorders
HUE053485T2 (hu)	2021-06-28	Készítmények és eljárások meibom-mirigy diszfunkció kezelésére
DK3291832T3 (da)	2025-12-08	Nanopartikelkompositioner til langvarig behandling
MA42135A (fr)	2018-03-28	Méthodes et trousses pour traiter la dépression
HUE054748T2 (hu)	2021-09-28	Béta-hexózaminidáz fehérje változatai és kapcsolódó eljárások GM2 gangliozidózis kezelésére
EP2968245A4 (fr)	2016-10-05	Compositions et méthodes de traitement de la stéatohépatite non alcoolique
EP3262169A4 (fr)	2019-02-06	Compositions et procédés de lutte contre des insectes nuisibles
EP3380062A4 (fr)	2019-07-24	Compositions pour le traitement des cheveux
BR112018001900A2 (pt)	2018-09-18	composições agonistas de trkb ou trkc e métodos para o tratamento de condições óticas
IL267592A (en)	2019-08-29	Preparations containing acetic acid and hypochlorous acid and methods for biofilm treatment
EP3394272A4 (fr)	2019-07-31	Compositions et procédés permettant de cibler efficacement des transgènes
EP3258925A4 (fr)	2019-01-09	Méthodes et compositions pour réduire la vidange gastrique
HUE054204T2 (hu)	2021-08-30	Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez
PL3280423T3 (pl)	2023-12-27	Kompozycje i sposoby do synergistycznego leczenia glikokaliksu
IL254963A0 (en)	2017-12-31	Preparations and methods for the treatment of autism
BR112017007790A2 (pt)	2018-07-17	método e aparelho de horticultura
FI20145633A7 (fi)	2015-12-31	Menetelmä biolietteen käsittelemiseksi
EP3359553A4 (fr)	2019-04-03	Compositions et procédés pour traiter la rétinopathie diabétique
EP3350338A4 (fr)	2019-07-17	Procédés et compositions pour détecter des mycotoxines
PL3220908T3 (pl)	2022-11-07	Kompozycje i sposoby leczenia endometriozy
EP3445369A4 (fr)	2020-03-04	Compositions et méthodes pour traiter la démence

Legal Events

Date	Code	Title	Description
2018-02-23	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-03-28	17P	Request for examination filed	Effective date: 20171123
2018-03-28	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-03-28	AX	Request for extension of the european patent	Extension state: BA ME
2018-05-09	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF V Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO Owner name: ALKAHEST, INC. Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
2018-08-22	DAV	Request for validation of the european patent (deleted)
2018-08-22	DAX	Request for extension of the european patent (deleted)
2018-12-05	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: ALKAHEST, INC. Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Owner name: U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF V Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO
2019-01-16	A4	Supplementary search report drawn up and despatched	Effective date: 20181219
2019-01-16	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 25/28 20060101ALI20181213BHEP Ipc: A61M 1/36 20060101AFI20181213BHEP Ipc: C12N 15/113 20100101ALI20181213BHEP Ipc: A61K 31/7088 20060101ALI20181213BHEP
2019-09-18	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Owner name: ALKAHEST, INC. Owner name: U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF V
2020-03-04	17Q	First examination report despatched	Effective date: 20200203
2021-03-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
2021-04-21	18W	Application withdrawn	Effective date: 20210316